Compare Incyte Corporation (INCY) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs STMicroelectronics NV — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while STMicroelectronics NV trades at $65.69 (market cap $55.80B). The key difference: STMicroelectronics NV is far larger — about 2.4× Incyte Corporation's market cap, and STMicroelectronics NV pays a 0.58% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | STM | |
|---|---|---|
Market Cap | $23.11B | $55.80B |
Sector | Health | Financials |
52-Week High | $118.52 | $79.91 |
52-Week Low | $67.38 | $21.20 |
Enterprise Value | $19.13B | $54.01B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
STM trades at $61.57, down 0.79% with a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 387.88 but strong analyst support (51.72% buy rating). Recent earnings have been inconsistent with two misses in the last three quarters, though Q3 2025 beat expectations. The company maintains solid cash flow generation of $555M in 2025 and is expanding AI partnerships with AWS and NVIDIA to drive future growth.
STM presents a cautious opportunity with 15% upside to the $72.33 consensus target, supported by AI expansion but tempered by declining revenue and thin 1.19% net margins. Key risks include execution on AI initiatives and semiconductor market volatility. The current price near support at $60 offers potential entry but requires monitoring of Q2 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
